Towards Healthcare
Middle East and Africa Cell and Gene Therapy Market to Grow at 23.85% CAGR til...

Middle East and Africa Cell and Gene Therapy Market Growth Path

Projections indicate that, the Middle East and Africa cell and gene therapy market will increase from USD 1.15 billion in 2024 to USD 9.75 billion by 2034, experiencing a CAGR of 23.85% over the next 10 years. The burgeoning biotechnology sector and the growing demand for personalized medicines drive the market.

Content

  • Last Updated: 08 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The Middle East and Africa cell and gene therapy market in 2025 is valued at USD 1.41 billion and is projected to climb to USD 9.75 billion by 2034, with a CAGR of 23.85% over the forecast period.

The Middle East and Africa cell and gene therapy market includes seven segments by therapy type, by therapeutic area, by vector/delivery type (for gene therapy), by cell source (for cell therapy), by manufacturing scale & service, by end-user, and by region.

Some key players include CureLeads, Opal Biopharma, Novartis, and Thermo Fisher Scientific.

CGT treats numerous disorders, including ADA-SCID, congenital blindness, hemophilia, Leber congenital amaurosis, and lysosomal storage diseases.

Gene therapy refers to the introduction of new genetic material into cells to restore the function of proteins.
Any Questions